RET fusion positive cancer
MONDO:0700216Neoplasm associated with expression of a RET (REarranged during Transfection) fusion. RET fusion-positive tumors have been identified in a broad range of solid tumor types, including multiple endocrine neoplasia 2 (MEN2), papillary thyroid carcinoma (PTC), non-small cell lung cancer (NSCLC), invasive breast cancers, and pancreatic ductal adenocarcinomas in addition to colorectal adenocarcinoma, melanoma, small cell lung cancer, neuroblastoma, and small intestine neuroendocrine tumors.
Also known as: RET fusion positive neoplasm, RET fusion positive solid tumor, RET fusion positive solid tumour
1444 clinical trials for this condition and its sub-types, 20 tagged with RET fusion positive cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New pill targets rare gene fault in advanced cancers
Disease control Recruiting nowThis study tests a new drug called TAS0953/HM06 in people with advanced solid tumors that have specific RET gene abnormalities. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks how well the drug shrinks tumors. About 244 adults with RET-altered non-small…
Phase 1/2 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug combo aims to shrink tough lung cancers
Disease control Recruiting nowThis Phase 2 trial tests a drug called ivonescimab, either alone or with chemotherapy, in people with advanced non-small cell lung cancer that has certain genetic changes. The study aims to see if the treatment can shrink tumors and control the cancer. About 46 participants will …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: Next-Gen RET inhibitor enters human trials
Disease control Recruiting nowThis study tests a new drug called EP0031 in people with advanced cancers that have a specific genetic change (RET alteration), including non-small cell lung cancer. The trial has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. About 265 adult…
Phase 1/2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Cancer drug pralsetinib may change how the body processes other medications
Knowledge-focused Recruiting nowThis study looks at how the cancer drug pralsetinib (Gavreto) affects the way the body breaks down other drugs and hormones. Researchers will give a cocktail of common medications and a hormone-based contraceptive to people with advanced solid tumors, then measure how pralsetinib…
Phase 4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC